Posts

BioNTech and BMS Announce First Global Data for PD-L1xVEGF Bispecific in Small Cell Lung Cancer, Set Phase 3 Dose

on

Servier Supercharges Neuro Pipeline with $450M Deal for Fragile X Syndrome Candidate

on

FDA Shifts Approach on GLP-1 Compounding: Announces Consumer Green List Instead of Immediate Crackdown

on

AstraZeneca Escalates EGFR Lung Cancer Rivalry with J&J: Tagrisso Combo Posts Survival Win

on

Daiichi and Merck's Lung Cancer ADC Achieves 48% Response Rate in Pivotal Trial

on

Rapport Reveals Promising Phase 2a Data for RAP-219 Epilepsy Pill, Plans Phase 3 Trials

on

Takeda’s Phase 3 Success Positions Oveporexton (TAK-861) as Potential First Mover in Multibillion-Dollar Narcolepsy Market

on

IQVIA Laboratories Bioinformatics Solutions Accelerate Genomic Insights for Drug Discovery in Partnership with NVIDIA

on

Junshi Biosciences Announces Phase 3 Win for IL-17A Drug JS005 in Psoriasis, Prepares China NDA Submission

on

Japan Wins Exemption for Generics in US-Japan Trade Deal

on

BioNTech and DualityBio Achieve Phase 3 Success with ADC Therapy for HER2-Positive Breast Cancer, Advancing Oncology Pipeline

on

RFK Jr. Blasts Pharma Industry and Spreads mRNA Vaccine Misinformation During Heated Senate Hearing

on

Recent Developments in Logistical Coordination for Decentralized Clinical Trials (DCTs)

on

MRM Health Nets $64M and Treeline Gathers $200M: Fierce Biotech Fundraising Tracker 2025

on

Survival Benefit of Amgen's Bemarituzumab in Gastric Cancer Attenuates at Final Analysis

on

FDA Pushes Back Agios' Pyrukynd Thalassemia Decision to December

on

Atlas Venture Raises $400M Opportunity Fund to Bolster Biotech Portfolio

on

FDA Releases Second Batch of Complete Response Letters, Moves to Real-Time Public Disclosure

on

Enveda Raises $150M Series D, Advances Nature-Inspired Drug Programs

on

RFK Jr. Faces Bipartisan Senate Criticism After CDC Shakeup

on

RFK Jr. Fires Top Deputies, Reshuffles Leadership at HHS

on

Wave RNA Editing Restores Enzyme in Genetic Disorder but Fails to Impress Investors

on

Sanofi Phase 3 Eczema Win Falls Short of Analyst Expectations

on

AC Immune Narrows Pipeline and Cuts 30% Workforce to Extend Cash Runway

on

AstraZeneca Ends Manufacturing License at Indian Plant and Exits Site as Part of Global Strategy

on

Endpoints News to Announce 2025 'Endpoints 11' Biotechs to Watch Live in Boston

on

FDA Launches New Submission Program for Rare Disease Gene Therapies via CDER and CBER

on

Wave Life Sciences Shares Dip After Mixed Data Update on GSK-Partnered AATD Therapy

on

Gilead Unveils New Manufacturing Site in California as Part of $32B U.S. Investment Plan

on

FDA Announces New Rare Disease Approval Programme

on

Novartis Again Partners with Argo Biopharma in $5.2B+ RNAi Cardiovascular Deal

on

Treeline Announces $200M Funding Boost, Moves Three Cancer Drugs into Clinic

on

UK Pharma Trade Group Calls for Overhaul of Government’s Life Sciences Investment Evaluation and Medicines Pricing Schemes

on

Paul Offit, RFK Jr. Critic, Removed from Key FDA Vaccine Panel

on

How Past Endpoints 11 Winners Fared During the 2025 Biotech Downturn

on

Recent News on Scaling Up Cell & Gene Therapy Supply Chains (2025)

on

Merck’s Oral PCSK9 Inhibitor Enlicitide Decanoate Achieves Third Consecutive Phase 3 Success

on

Amgen to Invest Over $600M in New Innovation Centre at California Headquarters

on

Ionis Builds Case for Wider Tryngolza Use in Severe Lipid Disorders Following Positive Phase 3 Results

on

Editas Medicine Reboots With Cholesterol Gene Therapy (EDIT-401) as Lead Asset

on